RNAC
Cartesian TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
RNAC Profile
Cartesian Therapeutics, Inc.
A clinical-stage biopharmaceutical company focused on Immune System
7495 New Horizon Way, Frederick, MD 21703
--
Cartesian Therapeutics, Inc., was incorporated in Delaware. The company is a clinical-stage company that has pioneered RNA cell therapies for the treatment of autoimmune diseases. The company's main asset, Descartes-08, is a potential first-in-class, RNA engineered chimeric antigen receptor T-cell therapy (rCAR-T), which is in Phase 2 clinical development in patients with generalized myasthenia gravis, and plans to conduct additional Phase 2 studies in systemic lupus erythematosus and ocular autoimmune and vascular autoimmune basket trials. Cartesian operates a wholly owned state-of-the-art cGMP manufacturing facility in Gaithersburg, Maryland.
